Parasol Medtech

Parasol is Personalized Solution to Left Atrial Appendage Closure, a medical device company developing next-generation solutions to prevent stroke in patients with atrial fibrillation (AFib). AFib disrupts the heart’s normal rhythm, causing the upper chambers of the heart to beat irregularly. This abnormal rhythm allows blood to pool in a small pouch of the heart called the left atrial appendage, where clots can form and potentially travel to the brain, resulting in stroke

Our Mission is to reduce stroke risk and improve patient outcomes by delivering safer, more precise, and more effective heart-based solutions.

Parasol was founded on the belief that stroke prevention should not rely on one-size-fits-all technology. Every patient’s heart anatomy is different, and medical devices should reflect that reality.

Meet Dr Atman Shah

Parasol Medtech Founder

I am an interventional cardiologist, Professor of Medicine at the University of Chicago, and clinician-founder focused on scalable innovation in structural heart disease. My expertise is in transcatheter interventions, particularly left atrial appendage (LAA) closure and minimally invasive stroke prevention and I close over 100 left atrial appendages annually and travel the world teaching other physicians on this technique and technology.

I am the founder of Parasol, a transcatheter LAA platform designed from first-hand operator experience and built around a patient-focused, evidence-first, and regulatory-clear pathway. My work sits at the intersection of patient care, clinical execution, trial driven de-risking, and scalable device commercialization.

Our Team & Advisors

Parasol Medtech is led by advisors with experience commercializing tech from UChicago, united by a shared focus: improving stroke prevention for patients with atrial fibrillation. Parasol’s leadership combines firsthand clinical insight with deep experience in medical device development. The company was founded to address real-world limitations seen in current stroke-prevention therapies, with an emphasis on safety, personalization, and long-term outcomes.

  • Alyssa Master, PhD

    Director, Venture Development Polsky Center for Entrepreneurship and Innovation

  • Benjamin Cox, PhD

    Senior Manager, Intellectual Property Polsky Center for Entrepreneurship and Innovation.

  • Steve Gould MD

    Consulting Director, Polsky Tech Ventures Founder, Gould Consulting.

  • Jennifer Fried, MBA

    Co-Founder, CEO
    Flow Medical

  • Jeff June

    CEO, Ischemia Care
    Forsythe Chair in Entrepreneurship Miami University, OH

What We’re Building

We are developing a novel, patient-specific left atrial appendage closure device designed to improve fit, sealing, and long-term safety. By prioritizing personalization and precision, our approach aims to:

  • Reduce procedural and post-implant complications.

  • Minimize residual leaks and clot formation.

  • Decrease reliance on lifelong anticoagulation for eligible patients.

Our device is being designed with clinical adoption, scalability, and regulatory pathways in mind.

Where We’ve Been .. And Where We’re Going

Contact us

We welcome inquiries from investors, strategic partners, clinicians, and collaborators who share our mission to improve stroke prevention in atrial fibrillation.

If you’re interested in learning more about Parasol Medtech, our technology, clinical roadmap, or investment opportunity, we’d be glad to connect

  • Email: info@parasolmedtech.com

  • Phone Number: 1 (773) 702-1372